HOME >> MEDICINE >> NEWS
Fogarty International Center announces new AIDS international training and research program grants

NATIONAL INSTITUTES OF HEALTH, BETHESDA, MARYLAND - The Fogarty International Center (FIC) of the National Institutes of Health (NIH) has awarded a total of $15 million to fund six new awards, three competing renewal awards, and 32 competing supplements to U.S. universities under the fourth funding cycle of the FIC AIDS International Training and Research Program (AITRP). As the international training arm of NIHs HIV research effort, AITRP trains developing country scientists to address the AIDS epidemic primarily through prevention research, combining biomedical and behavioral interventions.

AITRP supports U.S. grantees and their colleagues in Africa, Latin America, the Far East, Russia, and the New Independent States of the Former Soviet Union to build global HIV/AIDS research capacity and to help prevent HIV transmission. The program funds research and training programs for health scientists, clinicians, and allied health workers in parts of the developing world and newly emerging democracies severely impacted by the AIDS epidemic.

"We must prepare current and future generations of international scientists to work interdependently to meet global health needs," says FIC Director Gerald T. Keusch, M.D. "FICs AITRP is part of the NIH major effort to do so. First funded in 1988, AITRP is now the most extensive HIV research and training network among U.S. schools of medicine and public health and counterparts in developing nations."

Key areas of emphasis to date include intervention research designed to prevent HIV transmission among adults, as well as from mothers to childre
'"/>

Contact: Irene Edwards
ie3m@nih.gov
301-496-2075
NIH/Fogarty International Center
22-Oct-2000


Page: 1 2 3

Related medicine news :

1. Fogarty International Center announces first awards for international tobacco and health program
2. Fogarty International Center announces new research program in stigma and global health
3. Fogarty International Center announces initial awards for international studies on health and economic development
4. Fogarty International Center establishes Sheldon M. Wolff, MD Fellowship On International Health
5. International breast cancer prevention study launches in the United States and Canada
6. National Academies advisory: May 2 Symposium on International Science Policy
7. Awards & fellowships at the International & American Association for Dental Research General Session
8. Lectures, keynoters, symposia highlight International Dental Research meeting
9. Advances in Uterine Leiomyoma Research: 2nd NIH International Congress
10. International gathering of experts to share retinoblastoma breakthroughs
11. International trial of two microbicides begins

Post Your Comments:
(Date:4/17/2014)... signs of chronic inflammation in non-cancerous prostate tissue may ... cancer than those with no inflammation, according to results ... Johns Hopkins Kimmel Cancer Center. , The link between ... with so-called high-grade prostate cancer those with a ... presence of the most aggressive and rapidly growing prostate ...
(Date:4/17/2014)... a study published today in PLOS Pathogens , ... malaria is common can mount an immune response to ... avoid repeated bouts of high fever and illness and ... bloodstream. The findings may help researchers develop future interventions ... malaria parasite. , Each year, approximately 200 million cases ...
(Date:4/17/2014)... In a review published in the April issue of ... The Feinstein Institute for Medical Research, says it,s time ... approach to treating sepsis, which kills millions ... Sepsis occurs when molecules released into the bloodstream to ... body. Inflammation is necessary for maintaining good health ...
(Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
(Date:4/17/2014)... By discovering a new mechanism that allows blood to ... UC Irvine and the Salk Institute have opened the ... stroke-induced brain damage. , A complex and devastating neurological ... primary reason for disability in the U.S. The blood-brain ... blood-borne material into the brain, causing the permanent deficits ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Study IDs new cause of brain bleeding immediately after stroke 2
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... 2014 HeartWare International, Inc . (NASDAQ: ... miniaturized circulatory support technologies that are revolutionizing the treatment ... revenues for the fourth quarter of 2013 will be ... approximately $208 million. "Our full-year revenue growth ...
(Date:1/14/2014)... 14, 2014 InformEx, North America,s ... chemistry, will hold the 30 th edition of its ... Convention Center from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ... pharmaceutical, fine chemical and specialty chemical companies will take part ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
Cached News: